JP2025516590A5 - - Google Patents

Info

Publication number
JP2025516590A5
JP2025516590A5 JP2024566333A JP2024566333A JP2025516590A5 JP 2025516590 A5 JP2025516590 A5 JP 2025516590A5 JP 2024566333 A JP2024566333 A JP 2024566333A JP 2024566333 A JP2024566333 A JP 2024566333A JP 2025516590 A5 JP2025516590 A5 JP 2025516590A5
Authority
JP
Japan
Prior art keywords
antibody
sequence
heavy chain
seq
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516590A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/062651 external-priority patent/WO2023217987A1/en
Publication of JP2025516590A publication Critical patent/JP2025516590A/ja
Publication of JP2025516590A5 publication Critical patent/JP2025516590A5/ja
Pending legal-status Critical Current

Links

JP2024566333A 2022-05-12 2023-05-11 プログラム死-1タンパク質に対するモノクローナル抗体および医薬におけるその使用 Pending JP2025516590A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263364595P 2022-05-12 2022-05-12
US63/364,595 2022-05-12
PCT/EP2023/062651 WO2023217987A1 (en) 2022-05-12 2023-05-11 Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

Publications (2)

Publication Number Publication Date
JP2025516590A JP2025516590A (ja) 2025-05-30
JP2025516590A5 true JP2025516590A5 (enExample) 2026-05-19

Family

ID=86332322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566333A Pending JP2025516590A (ja) 2022-05-12 2023-05-11 プログラム死-1タンパク質に対するモノクローナル抗体および医薬におけるその使用

Country Status (6)

Country Link
US (1) US11932693B2 (enExample)
EP (1) EP4522654A1 (enExample)
JP (1) JP2025516590A (enExample)
AR (1) AR129303A1 (enExample)
TW (1) TW202413432A (enExample)
WO (1) WO2023217987A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12410258B2 (en) 2023-05-12 2025-09-09 Ganmab A/S Antibodies capable of binding to OX40, variants thereof and uses thereof
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
SI3708579T1 (sl) 2014-04-01 2024-09-30 Biontech Cell & Gene Therapies Gmbh Klavdin-6 specifični imunoreceptorji in T celični epitopi
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
MX2021010997A (es) * 2019-03-13 2021-10-01 Merck Sharp & Dohme Llc Terapias anticancerigenas combinadas que comprenden agentes bloqueadores ctla-4 y pd-1.
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CA3197951A1 (en) * 2020-11-11 2022-05-19 Ugur Sahin Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2022189667A1 (en) 2021-03-12 2022-09-15 Genmab A/S Non-activating antibody variants
IL311771A (en) 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against pd-l1 and cd137 in combination

Similar Documents

Publication Publication Date Title
CN119161491A (zh) 双特异性重组蛋白及其应用
CN113710271A (zh) 抗cd228抗体和抗体-药物缀合物
JP7851303B2 (ja) ヒトcd3イプシロンに結合する新規なヒト抗体
JP2025508066A (ja) 目的としたt細胞活性化のためのcd28二重特異性抗体
CA3196933A1 (en) Anti-cd3 antibody and uses thereof
CA3193664A1 (en) Anti-cd47 monoclonal antibody and use thereof
WO2019157353A1 (en) Immunotherapy for urothelial carcinoma
AU2020299382A1 (en) Monoclonal antibodies that bind EGFRvIII and their use
WO2021168169A1 (en) Anti-baff receptor antibodies and uses thereof
CN113574069A (zh) 抗pd-l1抗体及其用途
AU2019349662A1 (en) System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
JP2025508317A5 (enExample)
JP2023504531A (ja) 腫瘍治療のための二重特異性融合タンパク質と抗Her2抗体の組合せ
CA3256036A1 (en) Anti-PVRIG antibodies, pharmaceutical composition and associated uses
CN113825772A (zh) 抗her2亲合体及将其用作开关分子的可切换嵌合抗原受体
JP2024533457A5 (enExample)
TW202108631A (zh) 一種抗cd47抗原結合蛋白及其應用
JP7753401B2 (ja) ヒト化抗clec-1a抗体及びその抗原結合断片及びそのミメティック
JP5884139B2 (ja) Mhcクラスiiを発現する悪性腫瘍の治療薬
KR20230120125A (ko) Lgr5 및 egfr에 결합하는 항체를 사용하는 암의 치료
JPWO2016163433A1 (ja) 抗fgfr2抗体と他剤を含む組成物
US20260022165A1 (en) Antibodies targeting cell surface deposited complement protein c3d and use thereof
WO2012024659A2 (en) Antibody-based constructs directed against tyrosine kinase receptors
TW202540198A (zh) 雙特異性抗體樣蛋白以及彼之製造及使用方法
TW202540199A (zh) 靶向her2及her3之雙特異性四價抗體